Kane Biotech Inc. (TSXV:KNE)

Market Cap	6.16M -7.3%
Revenue (ttm)	38.72K -97.9%
Net Income	-2.70M
EPS	-0.02
Shares Out	205.21M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	148,100
Open	0.0250
Previous Close	0.0250
Day's Range	0.0250 - 0.0300
52-Week Range	0.0150 - 0.0500
Beta	0.31
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 4, 2026

About Kane Biotech

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG) for treating wounds and otic infections. Its wound care product portfolio inclu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: KNE

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 28, 2026

Data Sources Report a data error